State Street SPDR S&P Biotech ETF
424 hedge funds and large institutions have $5.82B invested in State Street SPDR S&P Biotech ETF in 2019 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 134 increasing their positions, 137 reducing their positions, and 67 closing their positions.
7% more funds holding in top 10
Funds holding in top 10: 14 → 15 (+1)
2% less repeat investments, than reductions
Existing positions increased: 134 | Existing positions reduced: 137
6% less funds holding
Funds holding: 451 → 424 (-27)
8% less capital invested
Capital invested by funds: $6.32B → $5.82B (-$504M)
16.58% less ownership
Funds ownership: 144.73% → 128.15% (-17%)
33% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 67
54% less call options, than puts
Call options by funds: $849M | Put options by funds: $1.85B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$261M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$84.3M |
| 3 |
Two Sigma Advisers
New York
|
+$63.4M |
| 4 |
DA
Duality Advisers
Miami,
Florida
|
+$44.5M |
| 5 |
Two Sigma Investments
New York
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$228M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$226M |
| 3 |
Goldman Sachs
New York
|
-$160M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$89.9M |
| 5 |
JP Morgan Chase
New York
|
-$67.3M |
XBI Hedge Fund Activity: Q2 2019 in Review
424 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2019, worth a combined $5.82B — down 8% from $6.32B a quarter earlier.
Sellers outnumbered buyers: 67 funds closed out of XBI and 45 opened new positions — a net loss of 22 holders — while 137 trimmed existing stakes and 134 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $261M. The largest seller was Morgan Stanley, cutting an estimated $228M.
- 424 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2019, down from 451 in Q1 2019.
- Funds reported $5.82B of State Street SPDR S&P Biotech ETF stock for Q2 2019, down 8% quarter-over-quarter.
- 45 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2019 and 67 closed out, a net change of -22 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2019 was BNP Paribas Financial Markets, an estimated $261M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2019 was Morgan Stanley, an estimated $228M sold.
Based on aggregated 13F filings for Q2 2019.